Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

2022496 citationsJournal Articlebronze Open Access

Authors

Maartje W. Rohaan · B. J. Medical College & Sassoon Hospital

Troels Holz Borch · B. J. Medical College & Sassoon Hospital

Joost H. van den Berg · B. J. Medical College & Sassoon Hospital

Özcan Met · B. J. Medical College & Sassoon Hospital

Rob Kessels · B. J. Medical College & Sassoon Hospital

Marnix H. Geukes Foppen · B. J. Medical College & Sassoon Hospital

Joachim Stoltenborg Granhøj

Abstract

In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).

Topics & Keywords

CAR-T cell therapy research Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 23, pp. 2113-2125

DOI: 10.1056/nejmoa2210233

Field-Weighted Citation Impact: 47.55

Command Palette

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Authors

Abstract

Topics & Keywords

Publication Details